510(k)

K120989: TRUE METRIX SELF-MONITORING BLOOD GLUCOSE SYSTEM, TRUE METRIX PROFESSIONAL MONITORING BLOOD GLUCOSE SYSTEM

FDA 510(k) · Nipro Diagnostics, Inc. · decided Apr 24, 2013

Key facts

510(k) number K120989
Device name TRUE METRIX SELF-MONITORING BLOOD GLUCOSE SYSTEM, TRUE METRIX PROFESSIONAL MONITORING BLOOD GLUCOSE SYSTEM
Applicant Nipro Diagnostics, Inc.
Product code NBW
Subsequent product codes JJX, LFR
Date received Apr 2, 2012
Decision date Apr 24, 2013
Decision Substantially equivalent (SESE)
Submission type Traditional
Review panel Clinical Chemistry
Medical specialty Clinical Chemistry

At a glance

  • None MAUDE adverse event reports
  • None Recall events
  • None UDI device identifiers (GUDID)
  • 1–9 Predicate devices cited
  • 1–9 Later submissions citing this device
  • 100–999 510(k)s with this product code
  • No 510(k) summary on file
  • Yes 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications